Healthcare / Medical DevicesNasdaqGM
$15.85
-0.62 (-3.76%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $1.9M · quality 16.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
38/100
D
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$136M
P/E
16.5x
↓EV/EBITDA
8.0x
↓ROE
729.6%
↑Gross Margin
77.1%
↑Debt/Equity
14.19
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2010–2025 · 15 años de histórico normalizado
Revenue CAGR
+31.5%
FCF CAGR
—
FCF margin
4.4%
FCF / Net income
0.16x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $44.1M · net income $11.8M · FCF $1.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||||||
| Revenue | $44.1M | $44.1M | $32.6M | $20.4M | $16.7M | $11.4M | $3.6M | $1.0M | $1.9M | $738527.00 | $1.4M | $965501.00 | $847367.00 | $800029.00 | $769217.00 | $802572.00 | $728446.00 |
| Net Income | $11.8M | $11.8M | $-33.1M | $-25.8M | $-10.3M | $-27.3M | $-30.9M | $-10.4M | $-11.6M | $-5.5M | $-6.4M | $-4.8M | $-6.0M | $-11.3M | $-6.4M | $-10.2M | $-14.9M |
| EBITDA | $19.4M | $19.4M | $-18.1M | $-9.2M | $4.8M | $-12.9M | $-24.9M | $-8.7M | — | — | — | — | — | — | — | — | — |
| EPS | 0.41 | 0.41 | -7.03 | -12.19 | -7.50 | -0.05 | -0.08 | -0.05 | — | — | — | — | — | — | -0.30 | -0.52 | -1.15 |
| Gross Margin | 77.1% | 77.1% | 75.2% | 70.4% | 74.1% | 70.5% | 79.8% | 47.6% | 62.5% | 67.2% | — | 70.5% | 74.0% | 76.3% | 71.4% | 67.4% | 65.6% |
| Operating Margin | 11.2% | 11.2% | 11.8% | -2.6% | -53.5% | -124.2% | -694.6% | -854.9% | -388.1% | -517.8% | -241.0% | -459.6% | -703.8% | -747.0% | -788.1% | -1097.6% | -1620.9% |
| Net Margin | 26.8% | 26.8% | -101.4% | -126.5% | -61.5% | -239.5% | -852.7% | -1013.9% | -628.7% | -749.9% | -467.9% | -498.2% | -705.0% | -1412.4% | -832.2% | -1275.7% | -2048.5% |
| Balance Sheet | |||||||||||||||||
| Debt/Equity | 14.19 | 14.19 | -1.63 | -0.71 | -0.95 | -0.02 | -0.01 | — | — | — | -0.78 | — | — | — | -0.82 | — | — |
| Current Ratio | 1.31 | 1.31 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | |||||||||||||||||
| Free Cash Flow | $1.9M | $1.9M | $2.0M | $-4.5M | $-17.2M | $-6.9M | $-12.8M | $-6.5M | $-3.7M | $-1.5M | $-3.2M | — | $-6.7M | — | $-4.3M | $-8.9M | — |
| Returns | |||||||||||||||||
| ROE | 729.6% | 729.6% | 209.5% | 59.8% | 25.1% | 70.0% | 225.5% | 103.6% | 75.7% | 56.0% | 93.2% | 81.8% | 385.1% | 184.4% | 98.2% | 666.4% | 141.9% |
| Valuation | |||||||||||||||||
| P/E | 16.51 | 16.51 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| EV/EBITDA | 7.98 | 7.98 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| P/B | 88.92 | 88.92 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | |||||||||||||||||
| Revenue Growth | 35.0% | 35.0% | 60.0% | 21.8% | — | 213.8% | 252.7% | -44.4% | 150.5% | -46.3% | 42.5% | 13.9% | 5.9% | 4.0% | -4.2% | 10.2% | — |
| EPS Growth | 105.8% | 105.8% | 42.3% | -62.5% | — | 37.5% | -60.0% | — | — | — | — | — | — | — | 42.3% | 54.8% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
50.8%
EPS terminal req.
$1.41
Spread vs growth
55.0%
5Y implied EPS CAGR
32.9%
EPS terminal req.
$1.70
Spread vs growth
72.9%
10Y implied EPS CAGR
20.9%
EPS terminal req.
$2.74
Spread vs growth
84.9%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-39.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-7.03 → 0.41
Residual
-39.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.